BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Israeli Ministry of Health
RESEARCH TRIANGLE PARK, N.C., Nov. 28, 2022 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Israeli Ministry of Health has granted marketing authorization for oral, once-daily ORLADEYO® (berotralstat) to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older in Israel.
This significant development represents a major milestone for BioCryst Pharmaceuticals, Inc. With the approval of ORLADEYO® by the Israeli Ministry of Health, patients suffering from hereditary angioedema (HAE) in Israel now have access to a new treatment option that has the potential to improve their quality of life. ORLADEYO® is an oral medication that is taken once daily to prevent attacks of HAE, a rare genetic disorder characterized by recurrent episodes of severe swelling in various parts of the body.
The approval of ORLADEYO® by the Israeli Ministry of Health is a testament to the safety and efficacy of this innovative medication. Clinical trials have shown that ORLADEYO® can significantly reduce the frequency and severity of HAE attacks, providing patients with greater stability and control over their condition. This approval also underscores BioCryst Pharmaceuticals, Inc.’s commitment to developing groundbreaking therapies for rare diseases and addressing unmet medical needs in the global healthcare landscape.
Impact on Individuals:
For individuals living with hereditary angioedema (HAE) in Israel, the approval of ORLADEYO® by the Israeli Ministry of Health offers new hope and the promise of improved treatment outcomes. Patients now have access to a once-daily oral medication that can help prevent HAE attacks and reduce the impact of this debilitating condition on their daily lives. With ORLADEYO®, individuals with HAE may experience fewer and less severe swelling episodes, leading to better control of their symptoms and improved quality of life.
Impact on the World:
The approval of ORLADEYO® by the Israeli Ministry of Health represents a step forward in the global effort to address rare diseases and improve patient care. By granting marketing authorization for ORLADEYO®, Israel is setting a precedent for other countries to follow in recognizing the value of innovative therapies for conditions like hereditary angioedema (HAE). This milestone highlights the importance of ongoing research and development in the field of rare diseases and the potential impact that new treatments can have on patients worldwide.
Conclusion:
In conclusion, the approval of ORLADEYO® by the Israeli Ministry of Health is a positive development for individuals with hereditary angioedema (HAE) in Israel and beyond. This milestone underscores the potential of innovative therapies to transform the lives of patients with rare diseases and highlights the importance of continued investment in research and development. As BioCryst Pharmaceuticals, Inc. continues to make strides in the field of rare diseases, the future looks brighter for individuals living with HAE and other challenging conditions.
